This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Findings

Claude de Montigny, MD, PhD, FRCPC

Arch Gen Psychiatry. 1989;46(6):511-517.

Abstract
• A total of 31 intravenous injections of the tetrapeptide cholecystokinin (30-33) were carried out in ten healthy subjects. In seven subjects, cholecystokinin-4 provoked a short-lasting (one to four minutes) panic-like attack (an intense unexplainable fear) at doses between 20 and 100 µg. In the other three subjects, doses of 80 to 100 µ induced severe anxiety, but no panic-like attack. All subjects experienced severe gastrointestinal symptoms. Pretreatment with lorazepam, but not with meprobamate or naloxone, prevented the psychic effects of cholecystokinin-4 in subjects who had experienced a panic-like attack with the same dose of this peptide. Following the peptide injection, levels of plasma free catecholamines, lactate, and glucose were unchanged, whereas levels of plasma cortisol and prolactin were increased. The intravenous injection of the sulfated cholecystokinin octapeptide (26-33) in two subjects (doses of 35 and 40 µg, respectively) produced severe gastrointestinal symptoms, but failed to induce any anxiety or panic-like attacks. These preliminary findings suggest that cholecystokinin-4 may have a panicinducing effect. It remains to be established if this peptide exerts this effect via a direct activation of central cholecystokinin receptors.

Author Affiliations
From the Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal.

Footnotes
Accepted for publication Sept 19, 1988.

Reprint requests to Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, 1033, ave des Pins ouest, Montreal (Quebec), Canada H3A1A1 (Dr de Montigny).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs
Gilles and Luthringer
J Psychopharmacol 2007;21:272-282.
ABSTRACT  

Induced Panic Attacks Shift {gamma}-Aminobutyric Acid Type A Receptor Modulatory Neuroactive Steroid Composition in Patients With Panic Disorder: Preliminary Results
Strohle et al.
Arch Gen Psychiatry 2003;60:161-168.
ABSTRACT | FULL TEXT  

Enhanced Cortical Extracellular Levels of Cholecystokinin-Like Material in a Model of Anticipation of Social Defeat in the Rat
Becker et al.
J. Neurosci. 2001;21:262-269.
ABSTRACT | FULL TEXT  

International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Noble et al.
Pharmacol. Rev. 1999;51:745-781.
ABSTRACT | FULL TEXT  

The cholecystokinin hypothesis of panic and anxiety disorders: a review
Bradwejn et al.
J Psychopharmacol 1992;6:345-351.
ABSTRACT  

Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorder: Clinical and Behavioral Findings
Bradwejn et al.
Arch Gen Psychiatry 1991;48:603-610.
ABSTRACT  

Cholecystokinin-4 and Panic
ABELSON and NESSE
Arch Gen Psychiatry 1990;47:395-395.
ABSTRACT